💉 #pharma #immunology

🇺🇸 $JNJ: #Tremfya sold $2.4bn in Q3, up 68%, while #Stelara fell 54% to $0.7bn under biosimilar competition.

Tremfya overtook it in Q4 2025, and J&J's immunology sales overall still grew 1.3%.

midgardfinance.com/companies/JNJ/